We have previously demonstrated that a short version of the E-cadherin promoter region containing the E-box sequences can be used to reflect an increase in CDH1 promoter activity upon EMT reversal.9 The discovery pipeline starts from the Phase 1 screening of a Food and Drug Administration (FDA)-approved drug library in a human ovarian cancer cell line harboring an intermediate EMT score, SKOV3, transiently transfected with the pGL3 luciferase plasmid containing the short promoter region of E-cadherin (Figure 1b, Supplementary Materials). The gene discussed is CDH1; the disease is ovarian cancer.